Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.59 |
| ▸ | CHRM2 known ✓ | P08172 | 7/20 | 0.55 |
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.55 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.55 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.53 |
| ▸ | CHRM4 known ✓ | P08173 | 4/20 | 0.52 |
| ▸ | CHRM5 known ✓ | P08912 | 4/20 | 0.52 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 0.52 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.52 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.52 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.50 |
| ▸ | GRIN1 known ✓ | Q05586 | 2/20 | 0.48 |
| ▸ | GRIN2A known ✓ | Q12879 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27583392 | 0.98 | IDO1 (0.59) | IDO1MAPTALDH1A1GAATAAR1 | |
| Bromide SCHEMBL3309563 | 0.95 | IDO1 (0.57) | IDO1MAPTALDH1A1GAATAAR1 | |
| SCHEMBL43208 | 0.81 | IDO1 (0.61) | IDO1MAPTALDH1A1GAATAAR1 | |
| Hydrochloric Acid SCHEMBL17318418 | 0.80 | SMN1; SMN2 (0.50) | IDO1ALDH1A1GAACA1CA2 | |
| SCHEMBL28858018 | 0.80 | TAAR1 (0.75) | IDO1MAPTALDH1A1GAATAAR1 | |
| SCHEMBL3296809 | 0.80 | IDO1 (0.61) | IDO1MAPTALDH1A1GAATAAR1 | |
| Hydrochloric Acid SCHEMBL27842350 | 0.79 | IDO1 (0.59) | IDO1MAPTALDH1A1GAATAAR1 | |
| Hydrochloric Acid SCHEMBL2493335 | 0.79 | IDO1 (0.59) | IDO1MAPTALDH1A1GAATAAR1 | |
| Hydrochloric Acid SCHEMBL27527127 | 0.79 | TAAR1 (0.67) | IDO1MAPTALDH1A1GAATAAR1 | |
| Hydrochloric Acid SCHEMBL9272901 | 0.79 | TAAR1 (0.67) | IDO1MAPTALDH1A1GAATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742047-B1 | ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-05-12 | — | — | EP | disclosed |
| US-10934272-B2 | Pyridyl derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| EP-3440069-B1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-10-28 | — | — | EP | disclosed |
| US-10407382-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3080085-B1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-08-14 | — | — | EP | disclosed |
| US-20190119248-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-04-25 | — | — | US | disclosed |
| EP-3440069-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2019-02-13 | — | — | EP | disclosed |
| EP-3152188-B1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2019-02-13 | — | — | EP | disclosed |
| CN-105814022-B | Condensed bicyclic heteroaromatic derivative as TNF active regulators | UCB生物制药私人有限公司 | 2018-09-28 | — | — | CN | disclosed |
| US-20180170858-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2018-06-21 | — | — | US | disclosed |
| CN-1684958-A | Dihydro-dibenzo (A) anthracenes and relative compounds,composition and method | LILLY CO ELI (US) | 2005-10-19 | — | — | CN | disclosed |
| EP-1546139-A1 | DERIVATIVE OF DIHYDRO-DIBENZO (A) ANTHRACENES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1527076-A1 | DIHYDRO-DIBENZO (B,E) OXEPINE BASED SELECTIVE ESTROGEN RECEPTOR MODULATORS, COMPOSITIONS AND METHODS | ELI LILLY AND COMPANY (US) | 2005-05-04 | — | — | EP | disclosed |
| US-20040267011-A1 | Methods for synthesis of diarylmethanes | DANA-FARBER CANCER INSTITUTE | 2004-12-30 | — | — | US | disclosed |
| WO-2004029047-A1 | DERIVATIVE OF DIHYDRO-DIBENZO (A) ANTHRACENES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-04-08 | — | — | WO | disclosed |
| US-6713471-B1 | SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-30 | — | — | US | disclosed |
| WO-2004009603-A1 | DIHYDRO-DIBENZO[B,E]OXEPINE BASED SELECTIVE ESTROGEN RECEPTOR MODULATORS, COMPOSITIONS AND METHODS | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2003031458-A1 | METHODS FOR SYNTHESIS OF DIARYLMETHANES | DANA-FARBER CANCER INSTITUTE (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-1192165-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000077010-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267011-A1 | Methods for synthesis of diarylmethanes | DHFR, DPYD, DHODH | GAA 1489/4885CHRM2 4285/4885CHRM1 4520/4885 |
| US-10934272-B2 | Pyridyl derivatives as bromodomain inhibitors | BRD4, BRD3, BRDT | GAA 1526/4885CHRM2 1532/4885CHRM1 1948/4885 |
| US-10407382-B2 | EP4 agonists as therapeutic compounds | PTGER4, PTGER1, PTGER3 | GAA 4754/4885CHRM2 725/4885CHRM1 744/4885 |
| US-20190119248-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | GAA 1526/4885CHRM2 1532/4885CHRM1 1948/4885 |
| US-20180170858-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | PTGER4, PTGER1, PTGER3 | GAA 4817/4885CHRM2 673/4885CHRM1 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.